Loading...

PODCAST

Pharmaceutical Executive

Pharmaceutical Executive Podcast

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

science life sciences

All Episodes

3:09

Pharmaceutical Executive Daily: What HCP Engagement...

Pharmaceutical Executive ·

2026/10/06

Shionogi, Gate Bioscience, and Alector post a trio of new deals, Rajul Jain makes the case for social listening as a medical affairs strategic tool, and Doceree's Vijay Adapala argues that HCP engagement is a systems-design problem, not a communications one.

en-us

27:05

AI and Patient Recruitment: Can Predictive Promise...

Pharmaceutical Executive ·

2026/10/06

Can artificial intelligence help turn what many believe is clinical development’s biggest variable — and most prevailing bottleneck — into a more predictable process? In this episode of the Pharm Exec podcast, Matt Walz, CEO of Trialbee, a patient recruitment company, joins Mike Christel, group managing editor, MJH Life Sciences, to discuss how AI is enhancing medical screening, clinical workflows, and enrollment planning. The conversation explores the need for clearer regulatory expectations,

en-us

3:11

Pharmaceutical Executive Daily: CSL & Alentis Enter...

Pharmaceutical Executive ·

2026/10/05

Jewel Jones warns that pharma catches patient disengagement too late, CSL and Alentis Therapeutics join Jiangsu Nhwa and Somnivera in a day of new licensing deals, and Corxel's Bo Liang calls GLP-1's leap to bariatric-surgery-level efficacy the biggest surprise in obesity medicine.

en-us

3:20

Pharmaceutical Executive Daily: Foghorn Therapeutics...

Pharmaceutical Executive ·

2026/10/02

Foghorn Therapeutics and Eli Lilly discontinue their SMARCA2 degrader program, Novartis licenses Abogen's autoimmune mRNA therapy while AstraZeneca, Daiichi Sankyo, and Summit Therapeutics team up on a breast cancer combination trial, and Corxel's Bo Liang makes the case for oral GLP-1 therapies.

en-us

2:53

Pharmaceutical Executive Daily: FDA Approves Expanded...

Pharmaceutical Executive ·

2026/10/01

Regeneron and Sanofi expand their antibody alliance with four new drug candidates, FDA approves Camzyos for adolescents with obstructive hypertrophic cardiomyopathy, and Michael Abrams questions digital health's savings claims to employers.

en-us

2:54

Pharmaceutical Executive Daily: Peptide Ruling Stalls

Pharmaceutical Executive ·

2026/09/30

Novo Nordisk data show real-world weight loss after switching to its oral semaglutide pill, FDA's peptide rulemaking stalls while its enforcement arm targets compounded peptide sellers, and Avi Pardo flags a compliance blind spot in field teams' text messages with doctors.

en-us

35:53

A Leadership Call to Action for Biotech

Pharmaceutical Executive ·

2026/09/30

In this episode of Leading Edge with Ken Banta, Jeremy Levin, D.Phil, MB BChir, co-founder and executive chairman of Ovid Therapeutics, joins Banta, The Vanguard Network founder and CEO, for a wide-ranging and candid discussion on the challenges confronting the U.S. biotechnology industry and the leadership required to strengthen its future. Drawing from Levin’s book, Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust, the prominent and outspoken biopharma leader argues that

en-us

3:07

Pharmaceutical Executive Daily: Fabrice Chouraqui...

Pharmaceutical Executive ·

2026/09/29

New U.S. guidance carves out tariff exemptions for specialty pharmaceuticals, Pharming's Fabrice Chouraqui steps down as CEO amid a board rift, and a dealmaking roundup covers Hengrui Pharma's licensing agreement with Novo Nordisk and AstraZeneca's investment in Summit Therapeutics.

en-us

3:13

Pharmaceutical Executive Daily: Merck Acquires...

Pharmaceutical Executive ·

2026/09/28

Merck licenses a preclinical KRAS G12D inhibitor from SciBrunch, FDA approves Olumiant, Juvmo, and Atebrioz across three separate indications, and Matthew Montes de Oca makes the case for compounding pharmacies to set their own safety standards.

en-us

3:24

Pharmaceutical Executive Daily: FDA Approves Welireg...

Pharmaceutical Executive ·

2026/09/25

FDA approves Merck and Eisai's Welireg-Lenvima combination for advanced kidney cancer, a platform-deal roundup covers Novo Nordisk, Genentech, and Roche's tie-ups with Nanexa, Earendil Labs, and Atavistik Bio, and Ron Lanton examines the fight to regulate pharmacy benefit managers.

en-us

2:54

Pharmaceutical Executive Daily: FDA Approves Onswik

Pharmaceutical Executive ·

2026/09/24

InnoCare Pharma and Eli Lilly ink a multibillion-dollar research collaboration, FDA approves Lilly's once-weekly insulin Onswik for type 2 diabetes, and Jen Lamppa talks fixing clinical trial patient enrollment with real-world data.

en-us

3:01

Pharmaceutical Executive Daily: Mike Doustdar Open to...

Pharmaceutical Executive ·

2026/09/23

EVERSANA's Jen Norton talks about how AI is reshaping market access strategy, a new analysis from MIT and Harvard Business School names clinical data harmonization as the real barrier to enterprise AI adoption in life sciences, and Novo Nordisk's CEO says he's open to a direct NYSE listing.

en-us

2:56

Pharmaceutical Executive Daily: Nine European...

Pharmaceutical Executive ·

2026/09/22

Nine major European drugmakers warn the region risks losing pharma investment, Novartis licenses a preclinical radioligand therapy asset from BoomRay Pharmaceuticals, and Rafaat Rahmani argues that the costliest competitive intelligence failure is missing the moment a strategic assumption goes wrong.

en-us

3:11

Pharmaceutical Executive Daily: AbbVie Forms...

Pharmaceutical Executive ·

2026/09/21

en-us

3:07

Pharmaceutical Executive Daily: FDA Approves Fayuvi

Pharmaceutical Executive ·

2026/09/18

FDA approves Ultragenyx's Fayuvi as the first treatment for Sanfilippo syndrome type A, Lisata Therapeutics acquires Marea Therapeutics as mAbxience partners with Sandoz on a hemophilia A biosimilar, and Joe Cunningham argues that executive drug-pricing deals alone won't fix costs.

en-us

3:29

Pharmaceutical Executive Daily: FDA Approves New...

Pharmaceutical Executive ·

2026/09/17

FDA approves Kerendia as the first new treatment for kidney disease in type 1 diabetes in decades, Novo, Roche, and Aethlon Medical strike major deals and mergers with Orbis Medicines, Dualitas Therapeutics, and North Immunology, and Thani Jambulingam of Saint Joseph's University examines the fight to control the GLP-1 patient journey.

en-us

2:57

Pharmaceutical Executive Daily: Novo Partners with...

Pharmaceutical Executive ·

2026/09/16

Novo teams up with Anthropic on AI-driven drug discovery, Sling Therapeutics and Circle Pharma close major financing rounds, and IQVIA's Phil Ford makes the case for reimagining medical content as a loop rather than a pipeline.

en-us

3:17

Pharmaceutical Executive Daily: Sanofi & Cheplapharm...

Pharmaceutical Executive ·

2026/09/15

GSK is acquiring a trispecific T-cell engager from Chimagen Biosciences and Sanofi expanding its manufacturing partnership with Cheplapharm, Stewart Gandolf discusses why pharma marketing now has to write for both people and AI, and Dr. Elena Christofides explains why cortisol dysregulation may be the hidden reason some diabetes patients fail to respond to incretin therapies.

en-us

3:06

Pharmaceutical Executive Daily: Novo Nordisk Enters...

Pharmaceutical Executive ·

2026/09/14

Cellectis pivots from CAR-T to in vivo gene editing, Novo Nordisk rebrands as "Novo" to sharpen its competitive edge in obesity and diabetes care, and Wendy Short Bartie of Bristol Myers Squibb makes the case for reputation as a strategic currency.

en-us

2:56

Pharmaceutical Executive Daily: Novartis Shareholders...

Pharmaceutical Executive ·

2026/09/11

Novartis investors intensify pressure on the company's M&A strategy after a string of trial failures, Michelle Carnahan argues health care needs an orchestration layer rather than more point solutions, and Nacho Quinones and Aisling O'Loughlin make the case for synthetic advisory boards in biopharma decision-making.

en-us

461 results

Similar Podcasts

Planetterrian Daily

Patrick · Nerra Network

New Books in Science, Technology, and Society

New Books Network

Scifi Friday

Radio Memories Network

The Bio Report

Levine Media Group

Waterlines: How Water Shapes Our World

jaywen